Compare Global X Copper Miners ETF (COPX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Global X Copper Miners ETF trades at $85.6 (market cap $7.10B), while State Street SPDR S&P Biotech ETF trades at $152.9 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 2,871,128). Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| COPX | XBI | |
|---|---|---|
Market Cap | $7.10B | $10.11B |
Volume | 2,871,128 | 12,903,266 |
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $96.45 | $169.55 |
52-Week Low | $57.43 | $104.99 |
Typical Hold Time | 50 Days | 37 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX trades at $84.83, up 1.5% today, but technical indicators show a bearish trend with 17 sell signals versus 2 buy signals. The ETF faces resistance at $85 with support at $79. Recent news highlights copper's strategic importance for AI infrastructure and electrification, though analysts express caution about near-term global surplus projections despite strong copper price fundamentals.
The copper miner ETF offers exposure to the AI-driven copper demand story but faces headwinds from Federal Reserve policy uncertainty and potential global supply surpluses. While long-term electrification trends support the investment thesis, near-term volatility and miner underperformance relative to copper prices present both opportunity and risk for investors.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
